Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis

被引:0
作者
Nicholas S. Hendren
Lori R. Roth
Justin L. Grodin
机构
[1] University of Texas Southwestern Medical Center,Division of Cardiology, Department of Internal Medicine
来源
Current Heart Failure Reports | 2020年 / 17卷
关键词
Transthyretin amyloidosis; Retinol binding protein; Biomarkers;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:77 / 83
页数:6
相关论文
共 234 条
[1]  
Rapezzi C(2015)Cardiac amyloidosis: the great pretender Heart Fail Rev 20 117-124
[2]  
Lorenzini M(2012)Cardiac transthyretin amyloidosis Heart. 98 1546-1554
[3]  
Longhi S(2019)Clinical presentation, diagnosis and treatment of TTR amyloidosis J Neuromuscul Dis 6 189-199
[4]  
Milandri A(2018)Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis N Engl J Med 379 11-21
[5]  
Gagliardi C(2013)THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis Curr Med Res Opin 29 63-76
[6]  
Bartolomei I(2019)Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review Clin Auton Res 29 19-24
[7]  
Salvi F(2019)Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis Circulation. 140 16-26
[8]  
Maurer MS(2018)Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy N Engl J Med 379 1007-1016
[9]  
Dungu JN(2018)Inotersen treatment for patients with hereditary transthyretin amyloidosis N Engl J Med 379 22-31
[10]  
Anderson LJ(2018)A new staging system for cardiac transthyretin amyloidosis Eur Heart J 39 2799-2806